ABVC BIOPHARMA, INC.

Regulatory Filings • Aug 2, 2021

8-A12B 1 ea144954-8a12b_abvcbiopharma.htm FORM 8-A12B

Field: Rule-Page

Field: /Rule-Page

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-A

FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES

PURSUANT TO SECTION 12(b) OR (g) OF

THE SECURITIES EXCHANGE ACT OF 1934

ABVC BioPharma, Inc.

(Exact name of registrant as specified in its charter)

Nevada	98-1584130
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)
44370 Old Warm Springs Blvd., Fremont, CA 94538

Securities to be registered pursuant to Section 12(b) of the Act:

Title of each class to be so registered	Name of each exchange on which each class is to be registered
Common Stock, par value $0.001 per share	The Nasdaq Stock Market LLC

If this form relates to the registration of a class of securities pursuant to Section 12(b) of the Exchange Act and is effective pursuant to General Instruction A.(c) or (e), check the following box. ☒

If this form relates to the registration of a class of securities pursuant to Section 12(g) of the Exchange Act and is effective pursuant to General Instruction A.(d) or (e), check the following box. ☐

If this form relates to the registration of a class of securities concurrently with a Regulation A offering, check the following box. ☐

Securities Act registration statement or Regulation A offering statement file number to which this form relates:

333-255112

Securities to be registered pursuant to Section 12(g) of the Act:

None

Field: Rule-Page

Field: /Rule-Page

Field: Page; Sequence: 1

Field: /Page

Item 1. Description of Registrant’s Securities to be Registered

The securities to be registered hereby are the units, common stock and warrants to purchase shares of common stock of ABVC BioPharma, Inc. (the “ Company ”). The description of the units, common stock and warrants contained in the section entitled “Description of Securities” and “Description of Securities That We Are Offering” in the prospectus included in the Company’s Registration Statement on Form S-1 (File No. 333-255112) filed with the U.S. Securities and Exchange Commission on April 8, 2021, as amended from time to time (the “ Registration Statement ”), to which this Form 8-A relates, is incorporated herein by reference. Any form of prospectus or prospectus supplement to the Registration Statement that includes such descriptions and that is subsequently filed is also incorporated by reference herein.

Item 2. Exhibits

Pursuant to the Instructions as to Exhibits for Form 8-A, no exhibits are required to be filed, because no other securities of the Registrant are registered on The Nasdaq Stock Market LLC, and the securities registered hereby are not being registered pursuant to Section 12(g) of the Securities Exchange Act, as amended.

Field: Page; Sequence: 2

Field: /Page

SIGNATURE

Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereto duly authorized.

Date: August 2, 2021	ABVC BioPharma, Inc.
By:	/s/ Howard Doong
	Howard Doong Chief Executive Officer

Field: Page; Sequence: 3; Options: Last

Field: /Page